Stock analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Roth Capital reissued a “buy” rating on shares of Bio-Path in a research note on Friday, March 17th.
Bio-Path Price Performance
Shares of NASDAQ:BPTH opened at $1.71 on Wednesday. The company’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $1.62. The stock has a market capitalization of $13.61 million, a price-to-earnings ratio of -0.81 and a beta of 1.30. Bio-Path has a 1 year low of $1.18 and a 1 year high of $4.48.
Institutional Trading of Bio-Path
A number of hedge funds and other institutional investors have recently modified their holdings of BPTH. Virtu Financial LLC bought a new stake in shares of Bio-Path during the first quarter worth $38,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path during the second quarter worth $70,000. Mount Yale Investment Advisors LLC bought a new stake in shares of Bio-Path during the third quarter worth $81,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bio-Path during the third quarter worth $35,000. Institutional investors own 6.42% of the company’s stock.
Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
- Get a free copy of the StockNews.com research report on Bio-Path (BPTH)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.